JPWO2020120449A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020120449A5 JPWO2020120449A5 JP2021533341A JP2021533341A JPWO2020120449A5 JP WO2020120449 A5 JPWO2020120449 A5 JP WO2020120449A5 JP 2021533341 A JP2021533341 A JP 2021533341A JP 2021533341 A JP2021533341 A JP 2021533341A JP WO2020120449 A5 JPWO2020120449 A5 JP WO2020120449A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disorders
- disease
- pharmaceutical composition
- following group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 102000003621 TRPC5 Human genes 0.000 claims 2
- 101150042815 TRPC5 gene Proteins 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000001272 neurogenic effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012374 Depressed mood Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 208000025967 Dissociative Identity disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010013461 dissociative amnesia Diseases 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212059.2 | 2018-12-12 | ||
| EP18212059 | 2018-12-12 | ||
| PCT/EP2019/084373 WO2020120449A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512374A JP2022512374A (ja) | 2022-02-03 |
| JPWO2020120449A5 true JPWO2020120449A5 (enrdf_load_stackoverflow) | 2022-12-16 |
| JP7408662B2 JP7408662B2 (ja) | 2024-01-05 |
Family
ID=64665183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533341A Active JP7408662B2 (ja) | 2018-12-12 | 2019-12-10 | 置換キサンタン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12291532B2 (enrdf_load_stackoverflow) |
| EP (1) | EP3894409B1 (enrdf_load_stackoverflow) |
| JP (1) | JP7408662B2 (enrdf_load_stackoverflow) |
| CN (1) | CN113166150B (enrdf_load_stackoverflow) |
| WO (1) | WO2020120449A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
| CN118459461A (zh) * | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
| WO2024236027A1 (en) * | 2023-05-18 | 2024-11-21 | Boehringer Ingelheim International Gmbh | 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028815B1 (ru) | 2013-03-15 | 2018-01-31 | Хайдра Байосайенсиз, Инк. | Замещенные ксантины и способы их применения |
| JP6667093B2 (ja) | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| LT3652176T (lt) * | 2017-07-11 | 2022-02-25 | Boehringer Ingelheim International Gmbh | Pakeisti ksantino dariniai |
| EP3894409B1 (en) * | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
-
2019
- 2019-12-10 EP EP19820717.7A patent/EP3894409B1/en active Active
- 2019-12-10 US US17/312,831 patent/US12291532B2/en active Active
- 2019-12-10 CN CN201980081691.3A patent/CN113166150B/zh active Active
- 2019-12-10 WO PCT/EP2019/084373 patent/WO2020120449A1/en active IP Right Grant
- 2019-12-10 JP JP2021533341A patent/JP7408662B2/ja active Active